The HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir,
developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use …

ABSTRACT A critical determinant for early post-entry events, the HIV-1 capsid (CA) protein
forms the conical core when it rearranges around the dimeric RNA genome and associated …

The human immunodeficiency virus type 1 (HIV-1) capsid is a protein core formed by
multiple copies of the viral capsid (CA) protein. Inside the capsid, HIV-1 harbours all the viral …

Resting CD4 T cells resist productive HIV-1 infection. The HIV-2/simian immunodeficiency
virus protein viral accessory protein X (Vpx) renders these cells permissive to infection …

The nuclear pore complex (NPC) is a proteinaceous nanopore that solely and selectively
regulates the molecular transport between the cytoplasm and nucleus of a eukaryotic cell …

Summary Human myxovirus resistance 2 (MX2) can potently restrict HIV-1 and
herpesviruses at a post-entry step by a process that requires MX2 interaction with the …

Retroviruses exploit host proteins to assemble and release virions from infected cells.
Previously, most studies focused on interacting partners of retroviral Gag proteins that …

In the fullerene cone HIV-1 capsid, the central channels of the hexameric and pentameric
capsomers each contain a ring of arginine (Arg18) residues that perform essential roles in …

The size of the nuclear pore should, in principle, prevent HIV-1 entry. However, HIV-1 capsid
is able to gain nuclear pore entry. In a recent issue of Nature, Fu et al. and Dickson et al …

Nucleoporins (nups) in the central channel of nuclear pore complexes (NPCs) form a
selective barrier that suppresses the diffusion of most macromolecules while enabling rapid …